MMP9 and lung cancer: In addition to cerebrovascular diseases, SB-3CT shows anti-tumor ability in melanoma and lung cancer by inhibition of MMP-9 through the reduction of programmed death ligand 1 [66] and anti-inflammation ability in inflammatory corneal neovascularization by suppression of MMP-9 and VEGF-C together to reduce corneal lymphangiogenesis and macrophage infiltration [40].